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Diets rich in saturated fatty acids (SFAs) produce a
form of tissue inflammation driven by ‘‘metabolically
activated’’ macrophages. We show that SFAs, when
in excess, induce a unique transcriptional signature
in both mouse and human macrophages that is en-
riched by a subset of ER stress markers, particularly
IRE1a and many adaptive downstream target genes.
SFAs also activate the NLRP3 inflammasome inmac-
rophages, resulting in IL-1b secretion. We found that
IRE1a mediates SFA-induced IL-1b secretion by
macrophages and that its activation by SFAs does
not rely on unfolded protein sensing. We show
instead that the ability of SFAs to stimulate either
IRE1a activation or IL-1b secretion can be specif-
ically reduced by preventing their flux into phospha-
tidylcholine (PC) or by increasing unsaturated PC
levels. Thus, IRE1a is an unrecognized intracellular
PC sensor critical to the process bywhich SFAs stim-
ulate macrophages to secrete IL-1b, a driver of diet-
induced tissue inflammation.
INTRODUCTION
Chronic consumption of diets rich in fat, particularly saturated
fat, is associated with the accumulation of immune cells such
as macrophages and dendritic cells in metabolic tissues like
the white adipose. Subsets of these accumulating myeloid cells
(MCs) express inflammatory markers and secrete pro-inflamma-
tory cytokines that also comprise the response to lipopolysac-
charide (LPS) stimulation (Lumeng et al., 2007; Weisberg et al.,
2003), and targeting inflammatory pathways in these cell types
has alleviated diet-induced insulin resistance in animal modelsCell(Yuan et al., 2001; Solinas et al., 2007). More recent work shows
that adipose tissue macrophages (ATMs) from obese mice have
a pattern of ‘‘metabolic activation’’ (MMe) that is distinct from that
induced by LPS (MLPS) or other danger- and pathogen-associ-
ated molecular patterns (DAMPs and PAMPs; Xu et al., 2013;
Kratz et al., 2014). However, the molecular details and functional
consequences of MMe polarization are poorly understood.
Treating cultured bone-marrow-derived macrophages or den-
dritic cells (BMDMs and BMDCs) with saturated fatty acids
(SFAs) recapitulates many features of MMe polarization that are
seen in the ATMs of mice consuming diets high in saturated fat
(Nguyen et al., 2007; Suganami et al., 2007; Kratz et al., 2014).
These include not only the secretion of NF-kB-dependent MLPS
cytokines such as interleukin 6 (IL-6) and tumor necrosis factor
(TNF) (Shi et al., 2006), but also activation of the NLRP3 inflam-
masome (Wen et al., 2011), an intracellular protein complex
that assembles in response to DAMPs and PAMPs and catalyzes
the cleavage and maturation of the cytokines IL-1b and IL-18.
Because circulating IL-1b levels are elevated in diet-induced
obesity (DIO) and targeting IL-1b, its receptor, or components
of the NLRP3 inflammasome protects obese mice from glucose
intolerance and other metabolic consequences of DIO (Osborn
et al., 2008; Stienstra et al., 2010; Wen et al., 2011), there is inter-
est in understanding how SFAs activate the NLRP3 inflamma-
some. Prior studies have implicated reactive oxygen species
accumulation due to impairment of AMPK-regulated autophagy
in this process (Wen et al., 2011). Others have pointed to a stim-
ulatory role for ceramide production (Schilling et al., 2013), but
recent work suggests that de novo ceramide synthesis does
not contribute to SFA-induced NLRP3 inflammasome activation
(Camell et al., 2015). As such, the question remains unresolved.
SFA-treated MCs also display endoplasmic reticulum (ER)
stress and activate the unfolded protein response (UPR),
a key component of which is triggered by activation of the
ER stress sensor inositol-requiring enzyme 1-alpha (IRE1a).
Recognition of unfolded proteins in the ER lumen stimulatesReports 14, 2611–2623, March 22, 2016 ª2016 The Authors 2611
the endoribonuclease activity of IRE1a, which splices Xbp1
mRNA to its mature form for translation into the transcription fac-
tor X box binding protein 1 (XBP1). XBP1 promotes transcription
of genes comprising the ‘‘adaptive UPR’’ that together promote
restoration of ER homeostasis. More severe or sustained ER
stress hyperactivates IRE1a and relaxes its endoribonuclease
specificity, leading to degradation of a number of ER-associated
transcripts through a process termed regulated IRE1a-depend-
ent decay (RIDD). Engagement of the RIDD pathway promotes
cell death by apoptosis and is a component of the ‘‘terminal
UPR’’ (reviewed by Maly and Papa, 2014).
Recently, SFA treatment was demonstrated to activate IRE1a
by a mechanism independent of unfolded protein recognition
(Volmer et al., 2013) and that does not involve the extensive olig-
omerization of IRE1a that occurs in response to unfolded pro-
teins (Kitai et al., 2013). The relative impact of this novel mode
of IRE1a activation on the terminal and adaptive arms of the
UPR is unknown, as is the functional significance of SFA-
induced IRE1a activation in MMe polarization. Specifically,
although IRE1a was shown to mediate NLRP3 inflammasome
activation via the RIDD pathway in pancreatic beta cells re-
sponding to unfolded protein accumulation (Lerner et al.,
2012), its role in SFA-induced NLRP3 inflammasome activation
in MCs is unknown.
Here, we identify that the transcriptional program defining
SFA-inducedMMe polarization is distinct from that of MLPS polar-
ization and is marked by a prominent ER stress signature, which
preferentially includes targets of IRE1a-dependent Xbp1 splicing
in both mouse and human macrophages. We show in mice that
excess dietary SFA consumption induces both Xbp1 splicing
and NLRP3 inflammasome activation within the ATM-rich
compartment of the white adipose tissue (WAT). Indeed, we
demonstrate that IRE1a is a critical mediator of SFA-induced
NLRP3 inflammasome activation in macrophages, and that
SFAs activate IRE1a by increasing the saturation of membrane
phospholipids.
RESULTS
SFA Treatment Produces a Transcriptional Signature
Distinct from LPS Treatment and Is Defined by the
Induction of Genes Associated with the ER and UPR
We usedmicroarray and functional enrichment analysis to probe
the transcriptional response of mouse macrophages to treat-
ment with specific fatty acid (FA) species at a concentration
known to reproduce the MMe polarization of ATMs (Kratz et al.,
2014). BMDMs were treated for 5 or 20 hr with stearic acid
(SA, 250 mM), a C18:0 SFA, or its C18:1 monounsaturated coun-
terpart oleic acid (OA, 250 mM) in complex with BSA. Responses
captured by microarray were compared to those following a 5-hr
treatment with BSA alone (control) or low-dose LPS (1 ng/ml).
Lists of genes significantly up- or downregulated by each treat-
ment in comparison to BSA are provided in Table S1.
LPS treatment resulted in a pro-inflammatory transcriptional
signature defined by the upregulation of 1,193 genes, enriched
as expected in those encoding factors involved in immune re-
sponses, cytokine and chemokine activity, and pattern recogni-
tion receptor signaling. However, SA treatment at either time2612 Cell Reports 14, 2611–2623, March 22, 2016 ª2016 The Authorpoint induced only 8% of the genes induced by LPS (Figure 1A),
and additional analyses revealed striking differences between
the transcriptional patterns induced by LPS and SA. For
example, although biological replicates within conditions were
tightly grouped, principal components analysis (PCA) showed
each individual treatment condition induced an overall transcrip-
tional response that was unique (Figure 1B). The responses to
LPS and SA (20 hr) defined the first two principal components,
as they were robustly separated both from the BSA-treated
baseline and from each other. The response to OA treatment,
by comparison, separated weakly from control along the first
two principal components, although somewhat further along
the third (Figure 1B). These findings together indicate that,
whereas OA treatment produces a relatively mild transcriptional
response, both SA and LPS treatments produce strong tran-
scriptional responses that are remarkably different from one
another despite the fact that each induces BMDMs to secrete
pro-inflammatory cytokines.
The distinct responses of BMDMs to FAs and LPS are also
clear when significant gene expression differences are grouped
and visualized as a heatmap (Figure 1C). Functional enrichment
analysis showed that, although 5 hr of SA treatment upregulated
the expression of genes encoding several chemokines and cyto-
kines, more prolonged SA treatment actually reduced the mRNA
levels of genes involved in immune responses and inflammatory
pathways. By contrast, the set of 433 genes induced by 20 hr of
SA treatment was most profoundly enriched in ER, UPR, Golgi
apparatus, and lysosome functional groups, a pattern that was
not seen in response to LPS treatment. On the other hand,
both LPS and SA (20 hr) treatments reduced the expression of
genes involved in functions related to cell division. BMDMs
treated with OA for 20 hr had a relatively anti-inflammatory tran-
scriptional profile, as seen in the heatmap by an opposing gene
expression pattern compared to LPS and downregulation of
genes involved in immune responses (Figure 1C).
The distinction between the transcriptional response of
BMDMs to SFA and LPS treatments was further underscored
by our analysis of BMDCs lacking Toll-like receptor 4 (TLR4),
which binds LPS. On one hand, TLR4 deficiency abolished the
ability of both LPS and long-chain SFAs (in this case, C16:0
palmitic acid [PA]) to increasemRNA levels of theMLPS inflamma-
tory marker Nos2 (Figure S1A). However, whereas TLR4 defi-
ciency abolished LPS-dependent secretion of the MLPS cytokine
TNF, it only minimally reduced PA-induced TNF secretion
(Figure S1B). Furthermore, treating BMDCs with the FA uptake
inhibitor sulfo-n-succinimidyl oleate (SSO) markedly reduced
PA-induced TNF secretion but did not alter the response to
LPS treatment (Figures S1C and S1D). Taken together, these
findings indicate that, whereas the LPS-induced inflammatory
response of BMDCs is entirely TLR4 dependent, a large compo-
nent of the low-grade inflammatory response to SFAs is TLR4 in-
dependent and instead requires intracellular FA uptake.
SFA Treatment Preferentially Induces Adaptive, but Not
Terminal, IRE1a Signaling in Both Mouse and Human
Macrophages
The ER and UPR-enriched transcriptional signature induced by
SA treatment in BMDMs included an upregulation of geness
Figure 1. SFA and LPS Treatments Induce
Distinct Patterns of Gene Expression in
BMDMs
(A) Venn diagrams depicting the distinct and in-
tersecting nature of gene sets whose transcription
is significantly regulated by treatment of BMDMs
with LPS (5 hr), stearic acid (SA, 5 hr or 20 hr), or
oleic acid (OA, 5 hr or 20 hr) as compared to
baseline vehicle control.
(B) Principal components analysis showing that
the treatment conditions above produce distinct
transcriptional responses. Each circle represents
one biological replicate of the indicated treatment
(n = 3–4).
(C) Heatmap showing categories of genes signifi-
cantly up- or downregulated in response one or
more of the treatments (indicated at left). Each
column represents one biological replicate of the
treatment indicated at the top. Boxes at right show
enrichment of functional categories (with Benja-
mini-Hochberg-corrected p values in parenthe-
ses) and representative genes that were either
significantly increased (green) or decreased (blue)
in expression in response to one or more treat-
ments.
See also Figure S1.involved in each of the three mammalian ER-stress-sensing
pathways (IRE1a, PERK, and ATF6). Notably, these genes
included IRE1a itself (Ern1) and several XBP1 target genes.
Indeed, the upregulated ATF6 target genes were largely shared
targets of XBP1. We therefore focused on IRE1a and asked
whether SA preferentially induced either the XBP1-dependent
adaptive aspects of IRE1a signaling or the IRE1a-dependent
pro-apoptotic RIDD pathway. Genes marking the XBP1-depen-
dent adaptive and RIDD responses, respectively, were compiled
from published studies (Lee et al., 2003; Acosta-Alvear et al.,
2007; So et al., 2012; Hollien et al., 2009; Maurel et al., 2014).
Those genes that were identified in at least two of the studies
we examined are listed in Figure 2A. Consistent with the reported
stimulation of Xbp1 splicing by SFAs inMCs and other cell types,
we found that all probes corresponding to the 25 ‘‘consensus’’
XBP1 target genes were numerically increased in BMDMs
treated with SA for 20 hr, and nine of these genes were signifi-
cantly upregulated. By contrast, SA treatment did not signifi-
cantly decrease the expression of any consensus genes known
to be downregulated by the RIDD pathway (Figure 2A).
In validating our microarray data, we also measured the
expression of six RIDD targets by qRT-PCR (qPCR) in BMDCs
treated for 4–72 hr with a higher dose of SA (500 mM) or thapsi-
gargin (positive control). Whereas thapsigargin treatment tendedCell Reports 14, 2611–2623to reducemRNA levels of several of these
genes, only one (Hgsnat) showed a RIDD-
like response to SA treatment (Figures
S2A–S2F). Consistent with this relative
lack of RIDD activity, treating BMDCs
with 500 mMPA or SA produced relatively
little caspase-3/7 activation or cell death
as compared to classical UPR inducersor staurosporine, a pro-apoptotic positive control (Figures S2G
and S2H). Together, these data indicate that SFAs activate pre-
dominantly the adaptive components of IRE1a signaling and
suggest that the SFA-induced UPR may not transition to the ter-
minal state that is triggered by the unremitting accumulation of
unfolded proteins.
To test whether the SA-induced IRE1a-XBP1 macrophage
signature we identified is conserved between mice and humans,
we performed ameta-analysis comparing the results of our 20-hr
SA treatment with those of a published bead array on SA-treated
human monocyte-derived macrophages (Xue et al., 2014). The
48 genes induced by SA in both species, shown in a heatmap
(Figure 2B), were significantly enriched by genes associated
with the ER, including 12 XBP1 targets. By contrast, there
were no RIDD-responsive genes downregulated by SA treat-
ment in both species (Figure 2B). Our meta-analysis further con-
firms that SFA treatment selectively induces adaptive IRE1a
signaling in macrophages and suggests that this response is
prominent in both mice and humans.
IRE1a Is Progressively and Reversibly Activated in Mice
Consuming Excess Saturated Fat
Next, we examined IRE1a activation in mice consuming a diet
rich in saturated fat. Transgenic mice expressing a luciferase, March 22, 2016 ª2016 The Authors 2613
Figure 2. SFA Treatment Preferentially In-
duces Adaptive, but Not Terminal, IRE1a
Signaling in BothMouse and HumanMacro-
phages
(A) Changes in the expression level of genes
associated with the adaptive UPR (XBP1 targets)
and the terminal UPR (RIDD targets). Differences
between the average log2 expression values for
each sample group are shown, with red bars
indicating significantly upregulated genes. Error
bars, SD.
(B) Heatmap showing the genes significantly up-
or downregulated in response to SA in bothmouse
BMDMs (this study, 20-hr treatment) and human
monocyte-derived macrophages (reanalysis of
data from Xue et al., 2014, 24-hr treatment). XBP1
targets are shown in red and RIDD targets in blue.
See also Figure S2.reporter coupled to the IRE1a-dependent splicing ofXbp1 (ERAI-
Luc; Iwawaki et al., 2009) were longitudinally monitoredwhile be-
ing fed standard chow or a high saturated fat diet (HFD; 42 kcal%
fat; 62% saturated). HFD consumption for 1–6 months progres-
sively increased whole-body ERAI-Luc reporter activity
compared to age-matched chow-fed mice, with the highest
signal intensity coming from the abdomen and proximal lower
limbs (Figures 3A and 3B). ERAI-Luc activity was evident within
5 days of HFD initiation and, despite up to 6 months of HFD,
was reversible within 5 days of replacing the HFD with standard
chow (Figures 3C and 3D). The changes in reporter activity we
observed support the concept that IRE1a activation in some tis-
sues may be rapidly responsive to changes in dietary fat con-
sumption and not a consequence of obesity per se.2614 Cell Reports 14, 2611–2623, March 22, 2016 ª2016 The AuthorsFocusing specifically on the WAT, we
found that feeding mice a HFD for
3 months increased the mRNA levels of
spliced Xbp1 and XBP1-dependent
target genes in the ATM-containing stro-
mal vascular fraction (SVF) of visceral
WAT depots (Figure 3E). Interestingly,
HFD-induced XBP1-dependent signaling
in SVF cells was concurrent with a sig-
nificant increase in the mRNA levels of
the gene encoding IL-1b (Il1b) and
the NLRP3 inflammasome component
Pycard (Figure 3F). These data suggest
that IRE1a activation in the visceral
ATMs of HFD-fed mice is accompanied
by NLRP3 inflammasome activation, as
it is in MCs treated with SFAs in vitro.
SFAs Act Intracellularly to Activate
IRE1a and the NLRP3
Inflammasome
We examined the mechanism by which
SFAs activate IRE1a in BMDCs from
ERAI-Luc mice. PA treatment induced
ERAI-Luc reporter activity in a dose-and time-dependent manner, with high PA concentrations
producing responses on par with those induced by treatment
with the classical UPR activators thapsigargin, dithiotreitol
(DTT), and tunicamycin (Figure 4A). Moreover, this response
was highly specific to long-chain SFAs (PA and SA) as
opposed to medium-chain SFAs or either long-chain monoun-
saturated or polyunsaturated FAs (Figure 4B). Similar SFA-
induced ERAI-Luc reporter responses were seen in BMDMs
(Figure S3A).
Building on work showing that SFAs stimulate myeloid cells to
secrete IL-1b, an NLRP3 inflammasome-dependent cytokine
(Wen et al., 2011), we found that treating LPS-primed BMDCs
with either SA or thapsigargin induced formation of intracellular
ASC puncta, indicating inflammasome activation, whereas OA
Figure 3. IRE1a Is Progressively and
Reversibly Activated in Mice Consuming
Excess Saturated Fat
(A) IRE1a-mediated Xbp1 splicing activity as
measured by a luciferase reporter (ERAI-Luc) in
live mice fed chow or a high-fat diet (HFD) for
6 months (representative images).
(B) Quantification of whole-body luciferase activity
in ERAI-Luc mice (n = 9–24) fed chow or HFD and
imaged as in (A).
(C) Whole-body IRE1a reporter activity in mice
before and after 5 days of HFD (n = 24).
(D) Reversal of IRE1a reporter activity in mice
switched to chow for 5–10 days after 6 months
of HFD.
(E) Expression of total and spliced Xbp1 and XBP1-
target genes Erdj4, Ero1l, and Dnajc3 as measured
by qPCR in the stromal vascular fraction (SVF)
of visceral adipose tissue (VAT) of mice fed chow
(n = 15–18) or HFD for 3 months (n = 8–10).
(F) Expression of NLRP3 inflammasome-related
genes Il1b, Nlrp3, and Pycard in VAT SVF as in (E).
Error bars, SD. *p < 0.05 versus chow unless
otherwise indicated.treatment did not do so (Figure 4C). SA and PA, but not OA, also
induced NLRP3 inflammasome-dependent IL-1b secretion in
LPS-primed BMDMs (Figure S3B).
On the other hand, LPS priming only minimally impacted SA-
induced ERAI-Luc reporter activity (Figure S3C), and LPS treat-
ment alone only modestly stimulated this indicator of Xbp1
splicing in BMDCs (Figure S3D). Whereas TLR4 deficiency
essentially eliminated the capacity of LPS to induce Xbp1
splicing in BMDCs, it had a much smaller impact on the corre-
sponding response to SA treatment (Figure S3D).
However, SSO treatment partially abrogated Xbp1 splicing
induced by PA or SA without impacting the responses to
classical UPR activators (Figure 4D), indicating that intracellular
entry, rather than TLR4, is required for SFAs to induce IRE1a-de-
pendent Xbp1 splicing. SSO treatment also abolished IL-1b
secretion from LPS-primed BMDCs stimulated with PA or SA,
whereas it did not alter IL-1b secretion in response to thapsigar-
gin or the canonical NLRP3 inflammasome activators ATP and
nigericin (Figure 4E). Treatment with PA or SA was notably insuf-
ficient to induce IL-1b secretion by BMDCs without LPS primingCell Reports 14, 2611–2623(data not shown), likely due to an inability
of SFAs to induce substantial Il1b tran-
scription on their own.
IRE1a Endoribonuclease Activity Is
Required for SFA-Induced NLRP3
Inflammasome Activation
IRE1a activation has been linked to
NLRP3 inflammasome activity in beta
cells (Lerner et al., 2012). This, and our
finding that intracellular SFAs induce
both IRE1a and NLRP3 inflammasome
activation, prompted us to consider
whether IRE1a mediates SFA-inducedNLRP3 inflammasome activation in MCs. To test this, we manip-
ulated IRE1a (Ern1) expression by treating BMDCs from mice
expressing a conditional allele of Ern1 (Ern1fl/fl) with a cell-
permeable Cre recombinase. This treatment reduced Ern1
mRNA levels by 63% (Figure 5A) and similarly reduced SFA-
induced IL-1b secretion without altering the response to ATP,
which stimulates IL-1b secretion without inducing ER stress (Fig-
ure 5B). We also crossed Ern1fl/fl mice with mice that preferen-
tially express Cre in MCs (Cd11b-Cre). Primary BMDCs cultured
from Cd11b-Cre+/Ern1fl/fl mice secreted less IL-1b in response
to PA treatment than did similarly treated BMDCs harvested
from Cd11b-Cre–/Ern1fl/fl mice (Figure 5C), although examina-
tion of Ern1mRNA expression suggested low Cre-LoxP excision
efficiency in this model (data not shown). Overall, our findings
indicate that IRE1a is required for SFA treatment to activate
the NLRP3 inflammasome.
IRE1a is a bifunctional protein with both kinase and endoribo-
nuclease activities. To determine which activity is responsible for
NLRP3 inflammasome activation, we treated WT BMDCs with
STF083010 and 4m8C, two specific IRE1a endoribonuclease, March 22, 2016 ª2016 The Authors 2615
Figure 4. Long-Chain SFAs Activate IRE1a
and the NLRP3 Inflammasome through an
Intracellular Mechanism
(A) Time course of IRE1a-mediated Xbp1 splicing
activity, as measured by a luciferase reporter in
mouse BMDCs (n = 2–3) treated with palmitic acid
(PA) or the classical ER stress inducers thapsi-
gargin (Tg, 100 nM), DTT (5 mM), and tunicamycin
(Tm, 5 mg/ml).
(B) Long-chain SFAs PA (C16:0) and SA (C18:0)
specifically induce IRE1a reporter activity in
BMDCs treated for 24 hr with a variety of FAs
(n = 3).
(C) Formation of ASC puncta indicative of NLRP3
inflammasome activation in BMDCs treated for
20–24 hr with SA (500 mM), thapsigargin (200 nM),
or nigericin (positive control), but not OA (500 mM)
or BSA (vehicle control for FA treatments).
(D) Inhibiting FA uptake with sulfo-n-succinimidyl
oleate (SSO, 500 mM) reduces IRE1a reporter ac-
tivity (n = 6) stimulated by SFAs (1 mM PA, 500 mM
SA) but not classical ER stress inducers (200 nM
Tg, 5 mg/ml Tm, 2.5 mM DTT).
(E) SSO specifically abrogates IL-1b secretion
induced by SFAs (500 mM) but not other stimuli
(n = 4). In all experiments measuring IL-1b secre-
tion, BMDCs were primed with LPS (200 ng/ml,
3 hr) prior to stimulation.
Error bars, SD. *p < 0.05 versus vehicle. See also
Figure S3.inhibitors. Remarkably, both inhibitors markedly decreased the
extent to which SFA treatment induced either Xbp1 splicing or
consequent IL-1b secretion (Figures 5D and 5E). Moreover,
they also reduced the ability of other ER stress inducers (e.g.,
thapsigargin) to activate the NLRP3 inflammasome without
altering the ability of ATP to do so. By contrast, treating BMDCs
with APY29, which is both an ATP-competitive kinase inhibitor
and an allosteric endoribonuclease activator of IRE1a (Wang
et al., 2012), failed to reduce SFA-induced IL-1b secretion and
was sufficient to induce IL-1b secretion on its own (Figure S4A).
Thus, the endoribonuclease activity of IRE1a in MCs specifically
mediates NLRP3 inflammasome activation in response to SFAs
and other inducers of ER stress.
Models of ER stress resulting from unfolded protein accumu-
lation showed that IRE1a promotes the RIDD-dependent induc-
tion of TXNIP, which associates with NRLP3 in the presence of
reactive oxygen species (ROS) and promotes inflammasome
activation (Lerner et al., 2012; Oslowski et al., 2012). As pre-
dicted by the relative lack of RIDD activity seen in SFA-treated
MCs (Figures 2 and S2), Txnip mRNA levels in BMDCs were
not increased by PA or SA treatment for durations of time over
which both thapsigargin and tunicamycin induced Txnip to
peak levels (Figure S4B). Indeed, SA did not increase Txnip at
any point over a 72-hr treatment (Figure S4C). Furthermore, the
antioxidants N-acetylcysteine and ebselen reduced IL-1b secre-
tion in response to treatment with thapsigargin, but not PA or SA
(Figure S4D). Our studies focused on TXNIP and ROS together
suggest that IRE1a mediates NLRP3 inflammasome activation2616 Cell Reports 14, 2611–2623, March 22, 2016 ª2016 The Authorby distinct mechanismswhen activated by SFAs versus classical
UPR activators.
SFAs andClassical UPRActivators InduceXbp1 Splicing
by Distinct Mechanisms
In addition to engaging stimulus-specific downstream effec-
tors of NLRP3 inflammasome activation, we found evidence
indicating that SFAs and chemical inducers of ER stress also
activate IRE1a by different mechanisms. In this effort, we stud-
ied MCs co-treated with unsaturated fatty acids (UFAs), which
can protect many cell types against several effects of SFA
exposure (Welters et al., 2004; L’homme et al., 2013). Co-
treating BMDCs with monounsaturated or polyunsaturated
UFAs dose-dependently abolished Xbp1 splicing in response
to PA without affecting responsiveness to thapsigargin, tunica-
mycin, or DTT (Figure 6A). Prolonged pretreatment with OA,
even when stopped prior to PA treatment, could reproduce
the protective effect of UFA co-treatment, but adding OA to
BMDCs after PA treatment was initiated could not reverse
Xbp1 splicing even if the PA was removed from the medium
(Figure S5A).
The ability of UFAs to block Xbp1 splicing induced by SFAs but
not classical UPR activators suggests that SFAs activate IRE1a
through a mechanism at least partly independent of unfolded
protein accumulation. To test this possibility, we treated BMDCs
with the chemical chaperones 4-phenylbutyric acid (PBA)
and tauroursodeoxycholic acid (TUDCA). PBA reduced Xbp1
splicing induced by classical UPR activators by 62%–65% buts
Figure 5. IRE1a Endoribonuclease Activity
Is Required for SFA-Induced NLRP3 Inflam-
masome Activation
(A) Extent of in vitro deletion of IRE1a (Ern1) by
treating Ern1fl/fl BMDCs with the cell-permeable
Cre recombinase HTNC, as measured by qPCR
(n = 3).
(B) IRE1a-deficient BMDCs from (A) exhibit
reduced IL-1b secretion when stimulated by SFAs
(500 mM, 20 hr) but not by ATP (n = 2–3).
(C) Partial deletion of IRE1a inCd11b-Cre+/Ern1fl/fl
BMDCs also modestly diminishes IL-1b secretion
stimulated by PA (500 mM, 24 hr) but not by ATP
(n = 4).
(D) Efficacy of IRE1a endonuclease inhibitors
STF083010 (200 mM) and 4m8C (50 mM) in reducing
IRE1a reporter activation by 24-hr treatment with
PA (1 mM), SA (500 mM), or classical ER stress
inducers (n = 6).
(E) STF083010 (200 mM) and 4m8C (200 mM)
abrogate IL-1b secretion stimulated by SFAs
(500 mM, 24 hr) but not ATP (n = 3). Error bars, SD.
*p < 0.05 versus WT + HTNC (A and B), Ern1fl/fl (C),
or vehicle (D and E).
See also Figure S4.only diminished SFA-induced Xbp1 splicing by 38%–45% (Fig-
ure 6B). Similarly, PBA and TUDCA abolished IL-1b secretion
in response to thapsigargin, but only partially reduced SFA-
induced IL-1b secretion (Figure 6C). Finally, combining PBA or
TUDCA with OA co-treatment did not add to the ability of OA
to abrogate SFA-induced Xbp1 splicing or IL-1b secretion (Fig-
ures S5B and S5C).
Together, these data suggest that although SFA treatment
may induce some degree of unfolded protein accumulation,
SFAs induce IRE1a activation through a mechanism that is at
least partially distinct from that by which unfolded protein accu-
mulation activates IRE1a. To test this, we built on emerging
evidence that IRE1a can be activated through an ability to sense
increases in ER membrane lipid saturation (Volmer et al., 2013).
We found that mouse embryonic fibroblasts that only express a
mutant form of IRE1a incapable of recognizing unfolded proteins
could still splice Xbp1 in response to PA treatment, even though
their ability to do so in response to tunicamycin was abolished
(Figure 6D).
Protein kinase RNA-like ER kinase (PERK) is another sensor of
ER stress and has also been implicated in membrane lipid
sensing (Volmer et al., 2013). Consistently, we found that the ki-
netics with which SA treatment of BMDCs phosphorylated PERK
was similar to those with which it phosphorylated IRE1a (Fig-
ure S6A). By contrast, ATF6a is an ER stress sensor that has
not been implicated in lipid sensing, and we found that SA treat-
ment of BMDCs induced little proteolytic processing or nuclear
translocation of ATF6a (Figure S6B). Taken together, these
data support the idea that SFAs can activate IRE1a and PERK
in BMDCs through changes in ER membrane composition but
that ATF6a activation requires unfolded protein accumulation
at levels beyond those induced by SFA treatment. Unlike the
impact of inhibiting IRE1a endoribonuclease activity, however,
PERK inhibition did not reduce SFA-induced IL-1b secretion
(Figure S6C).CellIntracellular SFAs Flux in a Way that Is Distinct from
UFAs and Not Controlled by UFA Levels
Intracellular UFAs are proposed to mitigate the lipotoxic ef-
fects of SFAs by promoting the flux of SFAs into triacylglycerol
(TG; Listenberger et al., 2003), which would potentially reduce
their availability to increase ER membrane lipid saturation and
thus stimulate IRE1a activation (Volmer et al., 2013). We
treated BMDCs with radiolabeled FAs and found that intracel-
lular OA accumulates preferentially in TG and cholesterol ester
storage pools, whereas PA fluxes predominantly into diacyl-
glycerol, phospholipid, and sphingolipid pools (Figures S7A
and S7B). However, to our surprise, we did not find that
co-treating BMDCs with OA affects the degree to which PA
fluxes into TG or any other lipid compartment, precluding
the possibility that OA exerts its protective effects in BMDCs
by boosting the incorporation of PA into TG (Figures S7C
and S7D).
Furthermore, altering the capacity of macrophages to form
TG had little impact on the ability of SFA treatment to activate
either IRE1a or the NLRP3 inflammasome. For example,
BMDCs from WT mice lacking the TG-synthetic enzyme
DGAT1 (Dgat1–/–) or transgenic mice overexpressing DGAT1
in MCs (aP2-Dgat1) did not substantially differ in their vulner-
ability to SFA-induced Xbp1 splicing (Figure S8A). Moreover,
neither genetic deficiency nor pharmacologic inhibition of
DGAT1 could impair either the capacity of SFA treatment to
induce IL-1b secretion or the protective effects of OA in
SFA-treated BMDCs (Figures S8B–S8E). These findings
support the concept that, rather than altering the flux of
SFAs into TG, the ability of UFAs to protect against
SFA-induced IRE1a activation and subsequent NLRP3
inflammasome activation is a function of their own flux into
phospholipids or other lipid species that may counteract
SFA-induced changes in membrane lipid composition and
saturation.Reports 14, 2611–2623, March 22, 2016 ª2016 The Authors 2617
Figure 6. Co-treatment with UFAs Specif-
ically Mitigates SFA-Induced IRE1a and
NLRP3 Inflammasome Activation
(A) UFA co-treatment of BMDCs dose-depen-
dently reduces IRE1a reporter activity stimulated
by PA but not by classical ER stress inducers
(2.5 mMDTT, 100 nM Tg, 5 mg/ml Tm, 24 hr, n = 3).
(B) In contrast to the SFA-specific protective effect
of OA co-treatment (100 mM, 24 hr), co-treatment
with the chemical chaperone 4-phenylbutyric acid
(PBA, 1 mM) mitigates IRE1a reporter activity
induced by both SFAs (1 mM PA, 500 mM SA) and
classical ER stress inducers (n = 6).
(C) Reduction of IL-1b secretion induced by SFAs
(500 mM, 24 hr, n = 3–4) and other stimuli by co-
treatment with the chemical chaperone taur-
oursodeoxycholic acid (TUDCA, 1 mM), PBA, or
OA as in (B).
(D) Xbp1 splicing measured by RT-PCR and gel
electrophoresis in mouse embryonic fibroblasts
expressing only wild-type (WT-IRE1a) or mutant
IRE1a lacking the luminal domain (DLD-IRE1a)
treatedwith PA (0.5–1mM) or Tm (5 mg/ml). PA and
Tm lanes were taken from separate sections of the
same gel.
Error bars, SD. *p < 0.05 versus control unless
otherwise indicated. See also Figures S5–S8.The Flux of SFAs into Phosphatidylcholine Contributes
to IRE1a and NLRP3 Inflammasome Activation
If SFA-induced IRE1a activation is a function of effects on ER
membrane lipid composition and saturation, as our data sug-
gest, then blocking the flux of SFAs into membrane lipids such
as phospholipids and sphingolipids should mitigate IRE1a acti-
vation and resultant NLRP3 inflammasome activation. Indeed,
inhibiting the first step of de novo sphingolipid and ceramide syn-
thesis with myriocin was shown to reduce IL-1b secretion in
macrophages co-treated with PA and LPS (Schilling et al.,
2013). However, more recent work has called this mechanism
into question (Camell et al., 2015), and we observed that myrio-
cin treatment did not significantly reduce IRE1a activation or
IL-1b secretion in response to PA (Figures S9A and S9B).
Phosphatidylcholine (PC) is the most abundant phospholipid
in mammalian cellular membranes, including those of the ER,
and we saw that BMDCs form PC to a greater degree upon treat-
ment with PA than OA (Figures S7A and S7B). As such, we
sought to determine the impact of limiting PC synthesis in
BMDCs treated with SFAs. The synthetic alkylphospholipids mil-
tefosine and edelfosine inhibit CDP:phosphocholine cytidylyl-
transferase (CCT), which catalyzes the rate-limiting step of PC
biosynthesis. Treatment with either miltefosine or edelfosine
reduced the ability of both PA and SA to induce Xbp1 splicing
and IL-1b secretion, suggesting that incorporation of SFAs into
PC contributes to the activation of IRE1a (Figures 7A and 7B).2618 Cell Reports 14, 2611–2623, March 22, 2016 ª2016 The AuthorsInterestingly, whereas CCT inhibition
was tolerated by untreated BMDCs and
those treated with SFAs, it caused perva-
sive cell death and reduced ERAI-Luc
reporter activity in cells treated with thap-sigargin, tunicamycin, or DTT (Figures 7A and 7C). Moreover
unlike its effect on SFA treatment, miltefosine did not reduce
Xbp1 splicing induced by thapsigargin and tunicamycin when
measured by qPCR (Figure 7D). This finding suggests that the
miltefosine-induced reduction in ERAI-Luc reporter activity
seen in the context of severe unfold protein accumulation is sec-
ondary to cell death and highlights the potential importance of
PC biosynthesis in the ability of BMDCs to contend with ER
stress under such conditions.
Our findings support the concept that SFA flux into PC leads to
IRE1aactivation and thatUFAscounteract this activation through
their own flux into phospholipids. We therefore reasoned that en-
riching MC membranes with unsaturated PC would be sufficient
to reproduce the protective effects of UFA co-treatment. BMDCs
were co-treatedwith SFAs and liposomes composed of dioleoyl-
phosphatidylcholine (DOPC). Remarkably, DOPC liposomes
(100–250 mM) abrogated SA-induced Xbp1 splicing (Figure 7E)
to adegree similar to that observedwithOAco-treatment at com-
parable concentrations (Figures 6B and 6C) and also reduced
Xbp1 splicing in response to thapsigargin (Figure 7E). Together
these data strongly support the concept that reducing the satura-
tion status of membrane phospholipids prevents activation of
IRE1a by SFA excess and decreases the sensitivity of IRE1a to
unfolded protein accumulation.
Importantly, and in correspondence with their effect on limiting
IRE1a activation, DOPC liposomes also protected against IL-1b
Figure 7. Limiting the Ability of SFA Treatment to Increase Phos-
pholipid Saturation Blocks Consequent IRE1a and NLRP3 In-
flammasome Activation
(A) Phosphatidylcholine biosynthesis inhibitors edelfosine (25 mM) and milte-
fosine (100 mM) reduce IRE1a reporter activity induced by SFAs (1 mM PA,
500 mM SA, 24 hr, n = 6).
(B) Edelfosine andmiltefosine co-treatment as in (A) diminishes IL-1b secretion
induced by SFAs (500 mM, 24 hr, n = 4).
(C) Miltefosine co-treatment potentiates cell death due to classical ER stress
inducers but not SFAs (500 mM, 24 hr, n = 4).
(D) Tg- and Tm-induced Xbp1 splicing is unaffected by miltefosine co-treat-
ment when measured by qPCR (n = 4), indicating that reductions in IRE1a
reporter activity in BMDCs co-treated with inhibitors and classical ER stress
inducers in (A) are secondary to cell death.
(E) Reduction of SA- and Tg-induced IRE1a reporter activity in BMDCs co-
treated with dioleoylphosphatidylcholine (DOPC) liposomes for 24 hr (n = 5).
(F) Abrogation of SFA-induced, but not ATP-induced, IL-1b secretion by DOPC
co-treatment of BMDCs (n = 3–4) as in (E).
Error bars, SD. *p < 0.05 versus vehicle (A–D) or control (E and F). See also
Figure S9.
Cellsecretion induced by SFAs or thapsigargin but not by ATP
(Figure 7F). Thus, shifting the equilibrium of cellular phospho-
lipids to favor higher unsaturation specifically abolishes the
ability of SFAs to induce IL-1b secretion without impairing the
responsiveness to DAMPs that are indicative of infection or
tissue damage.
DISCUSSION
Although ATMs chronically activated by DIO share features in
common with macrophages responding acutely to pathogens,
such as secretion of pro-inflammatory cytokines, key distinc-
tions exist that could potentially be exploited therapeutically
to combat inflammation-related metabolic dysfunction. Here,
we show that macrophages activated by SFA treatment
display a pronounced transcriptional signature of ER stress,
in striking contrast to the inflammatory signature induced by
stimulation with LPS. This ER stress response, driven by the
flux of SFAs to PC and resultant IRE1a activation, has func-
tional consequences. In particular, we found that SFA-induced
IRE1a endoribonuclease activity mediates activation of the
NLRP3 inflammasome and secretion of IL-1b, a pro-inflamma-
tory cytokine associated with insulin resistance. These find-
ings were corroborated in vivo, as we could progressively
increase tissue IRE1a activity by feeding mice a diet high in
saturated fat. Indeed, such a diet activated both IRE1a and
the NLRP3 inflammasome in the ATM-rich compartment of
the WAT. Thus, IRE1a activation among tissue MCs may be
important in promoting inflammation and metabolic disease
in DIO.
SFAs are thought to elicit pro-inflammatory TLR4 signaling in
MCs on account of their similarity to the saturated acyl chains
of LPS (Lee et al., 2001; Suganami et al., 2007), which bind spe-
cifically to TLR4 (Park et al., 2009). However, direct binding of
SFAs to TLR4 has never been demonstrated (Schaeffler et al.,
2009), though an adaptor protein, Fetuin A, has been proposed
(Pal et al., 2012). It has become increasingly clear that SFAs do
not merely mimic LPS (Erridge and Samani, 2009; Xu et al.,
2013; Kratz et al., 2014), and our microarray analysis under-
scores this point. Though SFAs do stimulate MLPS inflammatory
pathways and the secretion of associated cytokines such as TNF
from BMDCs, the magnitude of this response is small compared
to that induced by LPS or other PAMPs, and SFAs are insufficient
to substitute for LPS in priming the NLRP3 inflammasome.
Furthermore, we found that many of the responses to SFA treat-
ment are independent of TLR4 and instead require FA uptake,
suggesting that additional intracellular pathways mediate SFA-
induced macrophage activation.
Indeed, we demonstrate that activation of IRE1a via the flux of
SFAs into phospholipids and resulting induction of the UPR are
defining features of MC activation by SFAs. Previous transcrip-
tional and proteomic analyses of macrophages treated with
SFAs have revealed programs of lysosomal biogenesis and
intracellular lipid metabolism (Xu et al., 2013; Kratz et al.,
2014), but a predominant ER stress signature has not been
described. Differences in methodology may account for these
varying results. Nonetheless, our meta-analysis against SA-
treated human macrophages strongly confirms our findings inReports 14, 2611–2623, March 22, 2016 ª2016 The Authors 2619
mouse MCs and suggests that activation of IRE1a by SFAs is a
conserved process.
Our transcriptome analysis also reveals that SFA treatment
disproportionately induces the XBP1-dependent adaptive arm
of IRE1a signaling. Despite stimulating robust IRE1a activation,
evidenced by similar levels of Xbp1 splicing to those elicited by
thapsigargin and other UPR inducers, SFA treatment does not
result in an extensive RIDD response. This bias toward adaptive
IRE1a signalingmay outweigh the pro-apoptotic pathways asso-
ciated with the PERK arm of the UPR, as we observed little
apoptosis or cell death in BMDCs treated with SFAs despite a
significant level of PERK phosphorylation.
In models of prolonged or irremediable ER stress due to
unfolded protein accumulation, IRE1a undergoes a ‘‘switch’’
from adaptive to terminal signaling outputs, which is mediated
by a transition to higher-order oligomerization of IRE1a that pro-
motes RIDD (reviewed byMaly and Papa, 2014). Our results lead
us to speculate that activation of IRE1a in response SFAs does
not lead to extensive oligomerization of IRE1a. Consistent with
this hypothesis, SFA-treated cells expressing fluorescently
tagged IRE1a do not form the large IRE1a oligomeric puncta
that are seen following treatment with classical ER stress in-
ducers (Kitai et al., 2013). Thus, SFA treatment may represent
a paradigm in which progressive, dose-dependent Xbp1 splicing
does not trigger the typical switch-like behavior of IRE1a. This
SFA-induced mode of IRE1a activation appears to mediate
NLRP3 inflammasome activation by a different mechanism
than that which does so under conditions of excess unfolded
proteins, and the molecular features defining this mechanism
need to be explored. Based on this, our data suggest that dis-
rupting either Xbp1 splicing or XBP1-dependent transcriptional
activity may reveal new ways to control NLRP3 inflammasome
activation in the context of SFA excess and should be a focus
of future studies.
Though IRE1a is best known as a sensor of unfolded proteins,
its ability to directly sense changes in membrane lipid composi-
tion in mammalian cells was recently appreciated (reviewed by
Volmer and Ron, 2015). This ability of IRE1a to recognize and
respond to ER membrane perturbations may be critically linked
to its role in regulating lipid homeostasis. Activation of IRE1apro-
motes phospholipid synthesis in order to expand the capacity of
the ER during times of increased protein folding demand. The
importance of this adaptive response for cell survival was strik-
ingly evident in our studies, as BMDCs in which PC biosynthesis
was pharmacologically impaired did not survive treatment with
classical ER stress inducers. By contrast, inhibiting PC biosyn-
thesis did not cause such cell death in response to SFA treat-
ment, suggesting that the unfolded protein burden associated
with SFA-stimulated IRE1a activation does not necessitate ER
expansion to the degree that is required following treatment
with traditional UPR inducers.
Though we clearly show that the ability of IRE1a to recognize
unfolded proteins is not needed for its activation by SFAs, we
cannot completely rule out the possibility that unfolded proteins
may play some role in this process. For example, many chaper-
ones that facilitate protein folding require calcium, which is
depleted from the ER following SFA exposure (Wei et al., 2009;
Egnatchik et al., 2014). ER luminal calcium levels are maintained2620 Cell Reports 14, 2611–2623, March 22, 2016 ª2016 The Authorby the sarco/ER calciumATPase (SERCA), the activity of which is
impaired by obesity-induced changes in the PC/PE ratio of the
ER (Fu et al., 2011) or by enrichment of the ER with saturated
PC (Li et al., 2004). Given the partial protection we saw using
chemical chaperones, it is plausible that unfolded proteins could
accumulate secondary to SFA-induced changes in ER mem-
brane composition. However, any unfolded protein accumula-
tion due to SFA treatment is likely mild, as it did not appear to
engage the ATF6a arm of the UPR in our studies.
The ability of UFAs to mitigate the lipotoxic effects of SFAs are
well appreciated (Welters et al., 2004; L’homme et al., 2013), and
they have been proposed to do so by facilitating the incorpora-
tion of SFAs into TG and away from potentially deleterious meta-
bolic pathways (Listenberger et al., 2003; Coll et al., 2008; Leamy
et al., 2014). Consistent with this, we previously showed that
increasing TG synthesis capacity in MCs by overexpressing
DGAT1 was anti-inflammatory against SFAs in vitro or HFD
in vivo (Koliwad et al., 2010). Here, however, we found that OA
co-treatment did not enhance PA flux to TG, and that altering
DGAT1 activity or expression did not affect SFA-induced
IRE1a or NLRP3 inflammasome activation.
Instead, we found that co-treatment with DOPC reproduces
the protective effect of OA co-treatment, supporting the concept
that the flux of OA itself into PC and/or other phospholipids coun-
teracts the effect of SFA treatment on membrane saturation.
Furthermore, DOPC also protected against IRE1a activation
stimulated by thapsigargin, suggesting that increased mem-
brane fluidity may also limit the activation of IRE1a in response
to unfolded proteins. OA co-treatment does not have this effect,
but it may not alter ER membrane fluidity to the same degree as
direct supplementation with DOPC.
What are the physiological consequences of SFA-induced
IRE1aactivation inMCs?Weshowaprogressive rise in IRE1aac-
tivity in tissues of mice consuming a diet rich in saturated fat,
including the ATM compartment of WAT, and our findings imply
that MCs exposed to SFAs undergo a sustained form of IRE1a
activation that fails to resolve, yet does not transition to a terminal
program. As this unremitting form of IRE1a activation is coupled
with NLRP3 inflammasome activation both in vitro and in the
ATMs of mice fed a HFD, our findings could help explain what
promotes MCs in metabolic tissues to persistently propagate
metabolic inflammation in the context of DIO. Additionally, our
findings suggest that features of the chronic low-level inflamma-
tion seen in DIOmay be cell autonomous, and targeting the intra-
cellular pathways driving these programs could be effective in
limiting metabolic inflammation and its consequences.
However, prior efforts to block inflammatory pathways in the
context of DIO have been hampered by a lack of specificity
that is problematic, as general immunosuppression can result
in an unacceptable vulnerability to infection. Importantly, we
show here that inhibiting IRE1a, or the membrane perturbations
that lead to its activation, abolishes IL-1b secretion stimulated by
SFAs without affecting NLRP3 inflammasome activation in
response to other triggers associated with infection or tissue
damage. Though there are other implications of targeting this
pathway that require further study, we have uncovered a
mechanism for SFA-induced activation of IRE1a and the
NLRP3 inflammasome with translational implications relevants
to combating metabolic inflammation without impairing acute
inflammatory responses to pathogens.
EXPERIMENTAL PROCEDURES
Isolation of Primary Mouse Bone-Marrow-Derived MCs
All procedures were approved by the Institutional Animal Care and Use Com-
mittee at the University of California, San Francisco. Wild-type, ERAI-Luc (Iwa-
waki et al., 2009), Tlr4/ (Poltorak et al., 1998), Dgat1/ (Chen et al., 2002a),
and aP2-Dgat1 (Chen et al., 2002b) mice on a C57Bl/6 background and
Cd11b-Cre/Ern1fl/fl mice (Boille´e et al., 2006; Iwawaki et al., 2009) on a mixed
129/C57Bl/6 background were group housed and fed a standard chow diet
(LabDiet 5053) in a barrier facility with a 12-hr light-dark cycle. Bone marrow
cells were isolated from mice euthanized with Avertin and differentiated for
6–8 days in RPMI 1640 (GIBCO) containing 10% FBS (Atlanta Biologicals),
penicillin/streptomycin, and either recombinant GM-CSF (for BMDCs) or
M-CSF (for BMDMs; 10 ng/ml; PeproTech).
Microarray Sample Preparation
Replicate wells (n = 3–4) of WT BMDMs were treated with LPS (1 ng/ml), SA or
OA (250 mM), or BSA (125 mM) for 5 or 20 hr as indicated. Purified DNase-
treated total RNA was analyzed for quality using chip-based capillary electro-
phoresis (Bioanalyzer, Agilent) and quantity and purity was determined with a
NanoDrop spectrometer. The NuGEN Pico V2, based on Ribo-SPIA technol-
ogy, was used for amplification, fragmentation, and biotin labeling of 10 ng
input RNA. The labeled cDNA was hybridized to GeneChip Mouse Gene
1.0 ST microarrays (Affymetrix). Signal intensities of fluorescent images pro-
duced during GeneChip hybridizations were read by an Affymetrix Model
3000 Scanner and converted into GeneChip probe results files (CEL) using
Command and Expression Console software (Affymetrix).
Microarray Data Analysis
Data were quantile normalized and median centered across samples as
described (Baccarella et al., 2013). Differentially expressed genes were iden-
tified using Significance Analysis of Microarrays (Tusher et al., 2001) using
two-class unpaired comparisons with 3% false discovery rate (FDR) and
1.5-fold change cutoffs. Clustering was performed with xcluster (Gollub and
Sherlock, 2006) and visualized as heatmaps using Java Treeview (Saldanha,
2004). Gene set intersections were determined using custom Perl scripts.
Principal component analysis was performed in R. Functional enrichment
analysis utilized DAVID (Huang et al., 2009). Humanmonocyte-derived macro-
phage datasets were downloaded from the GEO (accession number
GSE46903) and processed identically to our mouse datasets. Only data
fromGM-CSF-derivedmacrophages treated for 24 hr with 150 mMSA and cor-
responding baseline controls were used in our analysis. The intersection of
mouse and human genes significantly induced by SA was identified using
custom scripts.
In Vivo Luminescence Imaging
Male ERAI-Luc mice (Iwawaki et al., 2009) fed chow or HFD (Harlan Teklad
TD.88137) starting at 4–6 weeks of age were imaged in the IVIS Spectrum
(PerkinElmer) under isoflurane anesthesia 10 min after intraperitoneal injection
of luciferin (150 mg/kg, GoldBio). Whole-body radiance was quantified using
Living Image software (PerkinElmer).
Cytokine Measurements
Cytokine levels in conditioned media were measured by Ready-Set-Go ELISA
kits (eBioscience). For all IL-1b secretion measurements, BMDCs were primed
with 200 ng/ml LPS (Sigma-Aldrich L4391) for 3 hr prior to FA treatment. Phar-
macological inhibitors, when used, were present during both priming and
treatment periods. ATP (Sigma-Aldrich A7699, 5 mM, 45–120 min) and niger-
icin (Calbiochem 481990, 5 mM, 1 hr) were used as positive controls.
In Vitro Deletion of Ern1 and Expression of Mutant IRE1a
Ern1fl/fl and control WT BMDCs were treated with HTNC (Excellgen RP-7) as
described (Krahmer et al., 2011). Ern1/ MEFs were rescued with full-lengthCellhuman IRE1a or human IRE1a lacking its luminal domain (DLD-IRE1a) by retro-
viral transduction as described (Volmer et al., 2013).
Statistics
Data are represented as mean ± SD and considered statistically significant at
p < 0.05. Outliers were removed according to Grubbs’ test (a = 0.05). Analyses
were performed in GraphPad Prism using two-tailed Student’s t test or ANOVA
with Holm-Sidak or Dunnett’s post tests in the case of multiple comparisons.
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